| Project/Area Number |
24659573
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kyoto College of Medical Science |
|---|
Principal Investigator |
ENDO keigo 京都医療科学大学, 公私立大学の部局等, 学長 (10115800)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
WATANABE Naoyuki 群馬県立県民健康科学大学, 公私立大学の部局等, 教授 (90311381)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | がん治療 / アルファ線 / 抗体 / ベータ線 / ＲＩ内用治療 / 放射線管理 / アスタチン211 / ＲＩ内用療法 / RI内用療法 / MIBG |
|---|
| Research Abstract |
Alpha-emitter;Astatin-211(half-life 7 hours), produced by using cyclotron, can be clinically applied for the therapy of cancer patients under current regulation in Japan. For further development of alpha-emitter therapy of cancer, the establishment of production system using cyclotron, relaxation of strict regulation, and the delivery of the alpha-emitter to research institutes will be useful in Japan.
Anti-tumor antibodies were labeled with beta-emitter yttrium-90 (half-life 3 days), injected into the tumor-bearing mice repeatedly, and showed inhibition of tumor progression. Animal-tumor model, established in the present study, would be used for the basic studies of alpha-emitter therapy of cancer.
|
